



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 914 831 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
12.05.1999 Bulletin 1999/19

(51) Int Cl.⁶: **A61K 39/42, A61K 39/23**
// C07K16/02, C07K16/04,
C07K16/08

(21) Application number: **98308655.4**

(22) Date of filing: **22.10.1998**

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(72) Inventors:
• **Mican, Petr**
593 01 Hustopece u Brna (CZ)
• **Stepanec, Jan**
592 56 Zvole na Perstynem (CZ)

(30) Priority: **04.11.1997 CZ 348997**

(74) Representative: **Lawrence, John Gordon et al**
McNeight & Lawrence
Regent House
Heaton Lane
Stockport, Cheshire SK4 1BS (GB)

(71) Applicant: **Medipharm CZ, s.r.o.**
693 01 Hustopece u Brna (CZ)

(54) **Biological product for preventive or therapeutic oral administration against canine parvovirus**

(57) Product for preventive and oral administration against canine parvovirus containing antibodies to canine parvovirus from colostrum of immunized cows and/or egg yolks of immunized laying hens. The product also contains stabilized live cultures of lactaciogenic bacteria. Production of antibodies to canine parvovirus con-

sisting in the immunization of the cows and/or laying hens with the canine parvovirus antigen, collection of the colostrum of the immunized cows and/or egg yolks of immunized laying hens, and adjustment of the obtained intermediate product into a form suitable for immunization of dogs, for instance by drying.

EP 0 914 831 A2

Description

[0001] The invention pertains to a product for the prevention and therapy of canine parvovirus.

[0002] The causative agent of the disease is canine parvovirus type II (CPV-2) known to exist in a single antigenic type that differs principally from the non-pathogenic type I parvovirus (CPV-1). The way infection of dogs by CPV-2 is almost exclusively oral. Owing to the strong affinity of the virus to rapidly propagating somatic cells, the infection concentrates particularly on epithelial cells of the small intestine. Myocardial cells tend to be also attacked by the virus in young pups. The infection induces degeneration and desquamation of enterocytes and exposure of the stroma of intestinal villi resulting in a considerable reduction of the absorption capacity of intestinal mucosa, hyperbiosis, transport of fluids from tissues into the intestinal lumen, dysbalance of intestinal microflora, and, in some cases, bacterial sepsis induced by facultative enteropathogenic germs (*Escherichia coli*, *Klebsiella* spp. *Pseudomonas* spp. and other species and genera). The clinical pattern of canine parvovirus is characterized by malignant vomiting, severe diarrhoea resulting in dehydration, and sudden death of pups if myocardium is affected.

[0003] Apart from oral administration of specific antibodies, no causal therapy of canine parvovirus is known. Therefore, the treatment of infected dogs concentrates on alleviation of clinical symptoms, support to defence mechanisms of the patient and inhibition of the development of secondary bacterial infections. Specific prophylactics of canine parvovirus are based on immunization with live or inactivated vaccines.

[0004] The insufficiency of the current therapeutic and immunoprophylactic methods for canine parvovirus is generally known. Their cases are summarized below.

[0005] Parvovirus is highly resistant to physical factors and chemical agents and survives in the environment in fully active state for prolonged periods.

[0006] Infected dogs shedding parvovirus into the environment with faeces are the only source of infection.

[0007] Most susceptible to parvovirus infection are pups lacking a fully competent immune system in the early post-natal period. Their resistance to infection depends on antibodies acquired during the embryonic phase (5%) and particularly on colostral antibodies (95%) absorbed during the first three days after birth. In other words, the resistance of pups to parvovirus infection depends on two very variable factors, i.e. the level of maternal immunity (concentration of antibodies to parvovirus in colostrum) and on the amount of colostrum taken during the first post-partum days.

[0008] Vaccination of adult dogs does not confer lifelong immunity to parvovirus infection. The immunity reaches its maximum on post-vaccination Days 28 to 35 and decreases thereafter. It is therefore necessary to vaccinate the dogs at least once per year.

[0009] The vaccination of pups is complicated by what is called "immune window", i.e. a period of two or four weeks when the level of colostral antibodies decreases below the protective threshold, but is still high enough to neutralize the antigenic effect of the vaccine. During this period, the pups are susceptible to infection but cannot be immunized effectively. The onset of the immune window is individually variable. Generally, it covers the period from 6th to 12th week after birth. Some authors are of the opinion that the period extends up to 16th week. This is apparently the reason why most of the vaccination programmes recommend to start the vaccination at the age of 6 weeks and repeat it at two-week intervals up to the age of 12 to 16 weeks.

[0010] The efficacy of specific prophylactics of canine parvovirus, such as vaccination or oral administration of antibodies, is significantly weaker, because the penetration of circulating antibodies to enterocytes of the small intestine as the primary infection site is rather difficult. The same mechanism limits the efficacy of colostral antibodies absorbed into the circulation.

[0011] Owing to its widespread occurrence and dramatic course, canine parvovirus is regarded as one of the most dangerous canine diseases associated with a high mortality rate, particularly in pups.

[0012] The above drawbacks can be removed to a considerable extent by the administration of the oral product for the prevention and therapy of canine parvovirus as to the invention, containing antibodies to canine parvovirus as the major active component. Further active components include stabilized cultures of lacticidogenic bacteria, such as *Enterococcus* spp. and/or *Lactobacillus* spp. with a protective effect, and vitamins with a supportive effect. Homogeneity of the product and standard contents of active components in the administration formulas, such as paste or powder, is ensured by mixing the active components with suitable vehicles. The efficacy of the product as to the invention consists in artificial induction of local immunity of the gastrointestinal mucosa of dogs, particularly pups, to parvovirus infection and in the support of general defence mechanisms of the treated animals. The major active component of the oral product are stabilized specific antibodies to parvovirus that neutralize canine parvovirus in the intestine, inhibit the initial phase of infection consisting in adhesion and penetration of virions into epithelial intestinal cells, and thus inhibit the infection or alleviate its severity.

[0013] The antibodies to canine parvovirus are obtained from non-conventional sources including colostrum of cows or eggs of laying hens immunized with the canine parvovirus antigen. The processing of the raw materials, such as bovine colostrum, or, preferably, egg yolks, consists only in careful preservation by spray or fluid drying, or preferably by freeze-drying. The resulting product is a white or yellow powder with a nutritional composition identical with that of

feed components commonly used in dog nutrition. The level of antibodies to canine parvovirus in the dried colostrum or egg yolk must reach at least the neutralization titre 16 for 100 TCID₅₀ (50% Tissue Culture Infection Dose) per 0.05 mg dried matter. The biological activity of the antibodies to parvovirus can be enhanced by combining them with a probiotic component ensuring restoration of eubiosis of the intestinal microbial biocenosis impaired by the parvovirus infection. Stabilized live cultures of lactacidogenic genera *Enterococcus* spp. or *Lactobacillus* spp. can inhibit the propagation of facultatively pathogenic bacteria in the intestine and thus prevent the risk of bacterial sepsis, or reduce it to a minimum. The probiotic component is manufactured by submersive pulsative culture of selected lactacidogenic bacterial strains. After separation from the medium, the cultures are stabilized by freeze-drying. The concentration of live bacteria should reach at least 50 x 10⁹ CFU (Colony Forming Units) per 1 g of the probiotic concentrate. To increase the general resistance to infections, the oral product can be supplemented with a vitamin component containing the vitamins A, C, D, E and group B either in loose form or as an oil suspension. The minimal daily doses for dogs should be 500 I.E. vitamin A, 35 I.E. vitamin D₃, 7 mg vitamin E, 1.2 mg vitamin C, 2 mg niacin, and 0.01 mg biotin. The product is intended largely for oral treatment of pups of various ages that are the highest risk of parvovirus infection. Therefore the following two formulas were chosen. The paste formula, packed in plastic applicators, is suitable for newborn and sucking pups and pups during the milk nutrition period. On the other hand, loose formula (powder or premix) allows easy mixing of the product with any feed type intended for weaned pups and dogs of any age, such as meat homogenates, canned meat, and granulated or extruded feeds. While the paste formula allows safe and accurate oral dosage onto tongue root without any risk of spitting out or unwanted dangerous aspiration, the powder formula is suitable for mixing into feeds for older and/or weaned pups and adult dogs of all age groups. The major components of the vehicle of the paste formula include colloidal silicone-hydrate and distilled monoglycerides that, along with a quality edible oil, form a consistent paste with a molecular mesh ensuring a homogeneous mixing of all active and carrier components. Unwanted microbial contamination of the product must be avoided during all phases of the manufacture of pastes including the filling into the plastic applicators. The final adjustment of the powder formula uses energy-rich carriers, such as glucose, lactose, sorbitol and starch along with dried skim milk or dried whey. The powder formula (pulvis, premix) can be mixed into feeds offered to pups prior to weaning. In order dogs, the product can be added into any feed types such as granulated or extruded feeds and wet meat mixtures.

[0014] The major merit of the product as to the invention consists in the possibility to overcome the drawbacks of the currently used preventive and therapeutic methods. Further merits are given below.

[0015] The product is manufactured of biological raw materials that are components of conventional dog feeds. It is absolutely non-toxic, hence there is no danger of overdosing even when administered by untrained persons, can be safely administered to pups and adult dogs of any age, can be used both to treat advanced stages of parvovirus infection and to prevent infection in animals exposed to increased infection pressures, such as those participating in dog shows, competitions, performance tests or housed in dog homes. Its administration can enhance the resistance of pups against parvovirus infection not only during the sucking period and weaning, but also before each transfer into another dog group or before any environmental change. The product as to the invention can also be administered to enhance the resistance of pups during the "immune window" period covering the age of 6 to 12 weeks. The locally administered antibodies do not interfere with the effect of parenteral vaccination and do not block the development of postvaccination immunity to canine parvoviro-sis. The formulas of the product, such as paste or powder, allow the optimal way of administration to all age categories of dogs eliminating the risk of aspiration in newborn and sucking pups.

Examples of materialization of the invention

[0016] The product for oral prevention and therapy of canine parvoviro-sis is manufactured by processing the elementary active components, vehicles and vitamin supplements to obtain any of the two basic administration formulas. While the paste is intended for sucking pups during the early postnatal period, the powder formula is intended for mixing into feed for older pups and adult dogs. The elementary active components of the product as to the invention are identical in both formulas.

[0017] Canine parvovirus (such as the strain CAPM, V-464, Collection of Animal Pathogenic Microorganisms, Hudcova 70, Bmo) propagated in susceptible cell cultures (such as the cell line CRFK, A-72) to reach haemagglutination titre (HT) of 512 to 1024, is used as the immunization antigen for obtaining antibodies to parvovirus. Eventually, the antigen is concentrated ten to twenty times by ultracentrifugation. Pregnant cows or laying hens, treated intramuscularly with 0.2 to 1.0 ml of the virus antigen premixed with an equal volume of an oil adjuvant, are used as antibody donors. The cows are immunized twice before the expected parturition and laying hens are immunized three times at 21-day intervals and subsequently as necessary, usually at three-week or four-week intervals.

[0018] The levels of antibodies to parvovirus are checked using haemagglutination inhibition or virus neutralization tests. The antibody titre is expressed in terms of reciprocal values of blood serum, colostrum, or egg suspension dilutions inhibiting 8 agglutination units or neutralizing the infection potential of TCID₅₀ of canine parvovirus.

[0019] The concentration of 16/100 TCID₅₀ of antibodies to canine parvovirus per 1 g product is necessary to achieve

the expected effect.

[0020] Cow's colostrum or egg yolks of the immunized donors must be thoroughly homogenized before further processing. The homogenized colostrum or egg homogenate is eventually preserved by spray or fluid drying, or, preferably, by freeze-drying. The resulting yellowish-white powder is kept in a dry and cold place up to the subsequent processing.

[0021] The probiotic concentrate is manufactured by submersion pulsative culture of selected strains of lactacidogenic bacterial species *Enterococcus faecium* M74 (CCM 6226) or *Lactobacillus casei* (CCM 3775) to obtain, after the separation of the medium and stabilization of the condensed biomass by freeze-drying, a dry bacterial concentrate containing at least 50×10^9 live cells per 1 g (CFU $50:10^9$ per 1 g). The probiotic concentrates are kept in a freezer at -18°C up to further processing.

Example 1

[0022] One of the final administration formulas of the product as to the invention may be a paste prepared by mixing the active components into vehicles ensuring homogeneity and thus the standard content of the former. Individual active components of the product as to the invention, including specific antibodies to canine parvovirus in the form of colostrum or egg yolks collected from immunized donor animals, the probiotic concentrate containing stabilized live lactacidogenic bacteria, and vitamin supplements, are stepwise mixed with the vehicle under vacuum in a special mixer.

Table 1:

Basic composition of the paste formula of the product	
Vehicle Components	w/w%
Quality edible oil (such as groundnut oil)	40 - 50
Colloid Siloid/hydrolysate (CABOSIL)	4 - 6.5
Distilled monoglycerides	1 - 3
Active Components	
Dried colostrum or egg yolks of immunized animals	18 - 45
Probiotic concentrate CFU 400×10^9 per 1 g (<i>Enterococcus faecium</i> , <i>Lactobacillus casei</i>)	1 - 2.5
Vitamin Supplement	
Mixture of vitamin concentrate (vitamins A, D ₃ , E C, K ₃ , B ₁ , B ₂ , B ₆ , B ₁₂ , biotin, niacin)	4 - 5

[0023] After thorough homogenization, the product as to the invention is filled into plastic applicators with a volume of 15 to 30 ml. The usual dosage ranges between 0.25 and 2 ml per animal a day.

Example 2

[0024] The final adjustment of the loose-powder (pulvis/premix) formula of the product as to the invention is carried out in standard mixers with horizontally and vertically moving blades to achieve the highest possible homogeneity of the product. To this end, the active components are first thoroughly premixed with a smaller amount of the vehicle and only then the mixer is completed to the full volume.

Table 2:

Basic composition of the power (pulvis/premix) formula of the product	
Vehicle Components	w/w%
Dried instant milk or dried whey	18 - 39
Active Components	
Glucose, starch, sorbitol	18 - 39
Dried colostrum or dried egg yolks from immunized donor animals	20 - 60
Probiotic concentrate (CFU: 400×10^9 per 1 g) (<i>Enterococcus faecium</i> M74 or <i>Lactobacillus casei</i>)	1 - 2

Table 2: (continued)

Basic composition of the power (pulvis/premix) formula of the product	
Vitamin Supplement	
Vitamin concentrate (A, D ₃ , E, C, K ₃ , B ₁ , B ₂ , B ₆ , B ₁₂ , biotin, cholin)	1-2

[0025] After thorough homogenization, the product as to the invention is filled into packages containing 100 to 250 g. The product is added to feeds for pups and dogs; the per day dose is 3 to 20 g, depending on the age, breed and body weight of the animal.

Claims

1. Product for preventative or therapeutic oral administration against canine parvovirus characterized by the content of antibodies to canine parvovirus prepared of colostrum of immunized cows and/or egg yolks of immunized laying hens.
2. Product for oral administration as to claim 1, characterized by the content of stabilized live cultures of lactacidogenic bacterial.
3. Product as to claim 1; characterized by the minimum concentration of 16/100 TCID₅₀ of antibodies to canine parvovirus per 1 g.
4. Product as to claim 1, characterized by the content of vitamins and vehicle substances.
5. Product as to claim 2, characterized by the content of Enterococcus spp. and/or Lactobacillus spp. as the stabilized live cultures of lactacidogenic bacterial species.
6. Product as to claim 5, characterized by the concentration of stabilized live cultures of lactacidogenic bacteria ranging from 100 x 10⁶ to 100 x 10⁹ live cells per 1g.
7. Product as to claim 1, characterized by the content of 18 to 60 w/w% of colostrum of immunized cows and/or egg yolks of immunized laying hens.
8. Product as to claim 4, characterized by the amount of vitamins corresponding to at least 100 I.E. for vitamin A, 10 I.E. for vitamin D₃, and 2 mg for vitamin E.
9. Product as to claim 4, characterized by the following w/w percentages of vehicle components: edible oil 45 to 60 w/w%, silicone hydrolysate 4 to 6.5 w/w%, and distilled glycerides 1 to 3 w/w%.
10. Product as to claim 4, characterized by the following w/w percentages of vehicle components: glucose and/or saccharose and/or starch 18 to 39 w/w% and dried instant milk and/or dried whey 18 to 39 w/w%.
11. Technology of production of antibodies to canine parvovirus, characterized by immunization of dairy cows and/or laying hens with canine parvovirus antigen, collection of colostrum of the immunized dairy cows and/or egg yolks of the immunized laying hens, and processing of the obtained substances into an administration form, such as drying.
12. Technology of the production of antibodies to canine parvovirus as to claim 11, characterized by the use of the strain CAPM V-464 of canine parvovirus as the antigen.